Supergut, the only nutrition brand clinically-validated to improve digestive health and curb cravings, is rolling out ...

Detailed price information for Bio-Path Holdings (BPTH-Q) from The Globe and Mail including charting and trades.

News Obese Children Are More Likely to Develop Skin Conditions Related to the Immune System. Childhood obesity can contribute to the development of common immune-mediated skin dis ...

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

A groundbreaking weight loss invention could soon make it possible to drop those extra pounds without a single change in your diet.

Amgen has downgraded Amgen from buy to hold saying that the potential for obesity asset MariTide is already included in the ...

Analysts say the number of private prescriptions for fat busting jabs like Ozempic in the UK are predicted to soar to over ...

Researchers have unveiled a novel approach to tackle obesity by targeting fat absorption in the small intestine. The ...

Groundbreaking research presented today at UEG Week 2024 reveals a promising new treatment strategy for type 2 diabetes (T2D) ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

However, GLP-1-based therapies aren't going to be the only option in the weight loss medicines market forever. Some companies are pursuing other approaches that could be even more effective or ...

Three Fool.com contributors have identified what they believe are no-brainer growth stocks to buy in October. Here's why they picked Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex ...